Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.76)
# 118
Out of 5,124 analysts
48
Total ratings
66.67%
Success rate
40.36%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRXS NeurAxis | Maintains: Buy | $7 → $8 | $4.54 | +76.21% | 2 | Dec 22, 2025 | |
| HROW Harrow | Maintains: Buy | $54 → $64 | $49.00 | +30.61% | 4 | Sep 23, 2025 | |
| INDV Indivior | Maintains: Buy | $27 → $34 | $35.88 | -5.24% | 5 | Aug 27, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $7.70 | +81.82% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $4.34 | +199.54% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $7.85 | +40.13% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $7.96 | +38.19% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $3.80 | -21.05% | 1 | Jul 1, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $16.59 | +2.47% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $16.91 | +65.58% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $18.46 | +111.27% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $3.37 | +137.39% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $10.10 | +107.92% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $5.80 | +3.45% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $6.77 | +77.25% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.04 | +24.38% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $21.55 | +6.73% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.78 | +53.06% | 2 | Jul 11, 2023 |
NeurAxis
Dec 22, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $4.54
Upside: +76.21%
Harrow
Sep 23, 2025
Maintains: Buy
Price Target: $54 → $64
Current: $49.00
Upside: +30.61%
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $35.88
Upside: -5.24%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $7.70
Upside: +81.82%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $4.34
Upside: +199.54%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $7.85
Upside: +40.13%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $7.96
Upside: +38.19%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $3.80
Upside: -21.05%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $16.59
Upside: +2.47%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $16.91
Upside: +65.58%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $18.46
Upside: +111.27%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.37
Upside: +137.39%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $10.10
Upside: +107.92%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $5.80
Upside: +3.45%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $6.77
Upside: +77.25%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.04
Upside: +24.38%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $21.55
Upside: +6.73%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.78
Upside: +53.06%